MedTrace Logo

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

NCT00546793 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-08-16

No results posted yet for this study

Summary

The purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of veltuzumab that was previously established when administered intravenously.

Conditions

  • NHL
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell
  • Lymphoma, Follicular
  • Lymphoma, Intermediate-Grade
  • Lymphoma, Large-Cell
  • Lymphoma, Low-Grade
  • Lymphoma, Mixed-Cell
  • Lymphoma, Small-Cell
  • Leukemia, Lymphocytic, Chronic
  • Leukemia, B-Cell, Chronic
  • Leukemia, Prolymphocytic
  • Leukemia, Small Lymphocytic
  • Lymphoma, Small Lymphocytic
  • Lymphoma, Lymphoplasmacytoid, CLL
  • Lymphoplasmacytoid Lymphoma, CLL
  • CLL
  • SLL

Interventions

BIOLOGICAL

veltuzumab

veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.

Sponsors & Collaborators

Principal Investigators

  • William Wegener, MD, PhD · Gilead Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546793 on ClinicalTrials.gov